One Size Fits All in Prostate Cancer: A Story Tale Whose Time has Come and Gone
Ammad Ahmad Farooqi et al, 2011, The International Journal of Biological Markers CrossRef
Systemic delivery of aptamer–drug conjugates for cancer therapy using enzymatically generated self-assembled DNA nanoparticles
Binh Thanh Tran et al, 2020, Nanoscale CrossRef
Increased expression of activated endothelial nitric oxide synthase contributes to antiandrogen resistance in prostate cancer cells by suppressing androgen receptor transactivation
Shan Yu et al, 2013, Cancer Letters CrossRef
Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Jian Zhang et al, 2013, Cancer Chemotherapy and Pharmacology CrossRef
CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells
D J Barakat et al, 2015, Oncogene CrossRef
Quercetin potentiates the chemosensitivity of MCF-7 breast cancer cells to 5-fluorouracil
Fatemeh Mawalizadeh et al, 2021, Molecular Biology Reports CrossRef
Synthesis, characterization and anti-tumor activity of Pd(II) complexes with 4,5-benzo-3H-1,2-dithiole-3-thione
Subhi A. Al-Jibori et al, 2019, Transition Metal Chemistry CrossRef
Updates on Overcoming Bicalutamide Resistance: A Glimpse into Resistance to a Novel Antiandrogen
Mehrnaz Izady et al, 2024, ACS Pharmacology & Translational Science CrossRef
Substitution of anti-androgens and tegafur-uracil combination therapy for castration-resistant prostate cancer: Results of a multi-center randomized phase II study
MASAYUKI TAKAHASHI et al, 2013, International Journal of Oncology CrossRef
HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro
Zhongbo Du et al, 2018, International Journal of Oncology CrossRef